🕒 Friday 28 August 2026 Fri, 28 Aug 2026

Provaris Energy reported a $4.045 million loss for FY2026 as it progressed proprietary hydrogen and liquid CO₂ storage technologies, expanded strategic partnerships, and boosted cash reserves through multiple placements.

Thorney Technologies Ltd posted a $16.4 million net loss for FY2026, deepening from last year, as it continued to simplify its portfolio and execute a substantial share buyback program.

RemSense Technologies reported a 27% revenue decline in FY2026 to $2.49 million due to project timing and economic uncertainty but secured major Tier-1 contracts and raised $1.21 million to fund technology development.

United Overseas Australia Ltd (ASX:UOS) reported a 10.3% rise in half-year revenue to $124.65 million for the period ended 30 June 2026, while net profit after tax fell 7.7% to $41.17 million. The company announced a combined interim and special dividend totaling 2.0 cents per share.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Clime Capital Limited (ASX:CAM) reported a sharp turnaround for FY26, with net profit after tax soaring 236% to $10.29 million, driven by strong unrealised gains and a higher income portfolio. The company sustained its steady dividend payments and pressed ahead with an active share and convertible note buyback program.

Queste Communications Ltd (ASX:QUE) posted a 66% increase in company-level profit for FY2026, but its consolidated entity, including Orion Equities (ASX:OEQ), saw earnings decline sharply amid weaker revenues and investment losses. No dividend was declared.

KKR Credit Income Fund has released the audited financial statements for its core investments as of December 31, 2025, revealing mixed returns and ongoing portfolio adjustments across multiple funds.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.

Energy Fuels Inc. has completed its acquisition of Australian Strategic Materials (ASM) through members’ and creditors’ schemes of arrangement, triggering ASM’s delisting from the ASX. Eligible ASM shareholders received a mix of Energy Fuels shares and cash, while optionholders were paid cash for their options.

Orion Equities (ASX:OEQ) returned to profitability in FY26 with a $204,000 net profit, buoyed by a $400,000 uplift in investment property value. Despite a 7% dip in total revenue, net tangible asset backing per share edged up to $0.43, while no dividend was declared.

FlexiRoam Limited (ASX:FRX) reported a statutory net profit after tax of $0.7 million for FY26, reversing a $2.0 million loss in FY25, driven by a pivot to higher-quality recurring revenue and operational discipline.

Castile Resources reveals a robust 2026 Scoping Study for its Rover 1 IOCG Project, projecting an 11-year underground mine life with five valuable metals driving strong economics and a staged development strategy.

OMG Group posted a 48% revenue increase to $6.13 million in FY26, achieving its highest-ever gross margin of 41% while expanding distribution into New Zealand and Southeast Asia.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Orcoda Limited reported a 26% reduction in net loss and a 23% rise in Annual Recurring Revenue, boosted by a new $8 million per annum multi-year contract with Wagner Corporation, setting the stage for SaaS expansion in FY27.

First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.

Papyrus Australia has expanded its TBS contract for an additional sample run after mixed trial results and secured a $200,000 unsecured loan with Irwin Biotech, advancing its capital raising efforts with L39 Capital.

Waterco Limited delivered a robust turnaround in FY26 with net profit after tax soaring 61.6% to $15.5 million on modest revenue growth. The company expanded its Swimart franchise, advanced manufacturing insourcing, and boosted dividends to 20 cents per share fully franked.

Jatcorp Limited's FY26 results show a 23% revenue increase to $38.9 million but a 41% larger loss attributable to owners. The company faces a material uncertainty over going concern despite improved statutory NPAT.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Staude Capital Global Value Fund Limited posted a 47% drop in net profit after tax for FY2026 amid a 39% revenue decline, while adjusted pre-tax NTA rose 7%. The company declared a fully franked final dividend of 3.3 cents per share and completed a $18.2 million share purchase plan last year.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.